A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model

Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development. Observations from preclinical mouse models and recent insights into the immunological effects caused by BRAFi give promise for future development of combination therapy for human m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellmann, Lydia, Cappellano, Giuseppe, Schachtl‐Riess, Johanna F., Prokopi, Anastasia, Seretis, Athanasios, Ortner, Daniela, Tripp, Christoph H., Brinckerhoff, Constance E., Mullins, David W., Stoitzner, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Tumor Immunology and Microenvironment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003881/
https://www.ncbi.nlm.nih.gov/pubmed/31702822
http://dx.doi.org/10.1002/ijc.32777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003881/
https://www.ncbi.nlm.nih.gov/pubmed/31702822
http://dx.doi.org/10.1002/ijc.32777

Ejemplares similares